JP2013525444A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525444A5
JP2013525444A5 JP2013508174A JP2013508174A JP2013525444A5 JP 2013525444 A5 JP2013525444 A5 JP 2013525444A5 JP 2013508174 A JP2013508174 A JP 2013508174A JP 2013508174 A JP2013508174 A JP 2013508174A JP 2013525444 A5 JP2013525444 A5 JP 2013525444A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
humans
treatment
following compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013508174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525444A (ja
JP5702853B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/034024 external-priority patent/WO2011137135A1/en
Publication of JP2013525444A publication Critical patent/JP2013525444A/ja
Publication of JP2013525444A5 publication Critical patent/JP2013525444A5/ja
Application granted granted Critical
Publication of JP5702853B2 publication Critical patent/JP5702853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013508174A 2010-04-27 2011-04-27 化合物 Active JP5702853B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32821210P 2010-04-27 2010-04-27
US61/328,212 2010-04-27
US32922510P 2010-04-29 2010-04-29
US61/329,225 2010-04-29
PCT/US2011/034024 WO2011137135A1 (en) 2010-04-27 2011-04-27 Chemical compounds

Publications (3)

Publication Number Publication Date
JP2013525444A JP2013525444A (ja) 2013-06-20
JP2013525444A5 true JP2013525444A5 (https=) 2014-05-22
JP5702853B2 JP5702853B2 (ja) 2015-04-15

Family

ID=44861895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013508174A Active JP5702853B2 (ja) 2010-04-27 2011-04-27 化合物

Country Status (39)

Country Link
US (1) US9040518B2 (https=)
EP (1) EP2563122B1 (https=)
JP (1) JP5702853B2 (https=)
KR (1) KR101769079B1 (https=)
CN (1) CN102858159B (https=)
AR (1) AR081337A1 (https=)
AU (1) AU2011245393B2 (https=)
BR (1) BR112012026767B1 (https=)
CA (1) CA2795543C (https=)
CL (1) CL2012003009A1 (https=)
CO (1) CO6612267A2 (https=)
CR (1) CR20120557A (https=)
CY (1) CY1118187T1 (https=)
DK (1) DK2563122T3 (https=)
DO (1) DOP2012000263A (https=)
EA (1) EA021753B1 (https=)
ES (1) ES2588743T3 (https=)
HR (1) HRP20161103T1 (https=)
HU (1) HUE029480T2 (https=)
IL (1) IL222365A (https=)
JO (1) JO3131B1 (https=)
LT (1) LT2563122T (https=)
MA (1) MA34235B1 (https=)
ME (1) ME02490B (https=)
MX (1) MX2012012527A (https=)
MY (1) MY162933A (https=)
NZ (1) NZ602754A (https=)
PE (1) PE20130384A1 (https=)
PH (1) PH12012502128B1 (https=)
PL (1) PL2563122T3 (https=)
PT (1) PT2563122T (https=)
RS (1) RS55079B1 (https=)
SG (1) SG184812A1 (https=)
SI (1) SI2563122T1 (https=)
SM (1) SMT201600293B (https=)
UA (1) UA110338C2 (https=)
UY (1) UY33353A (https=)
WO (1) WO2011137135A1 (https=)
ZA (1) ZA201207858B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3400944T3 (pl) 2010-11-04 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
CA2845845A1 (en) 2011-08-31 2013-03-07 Mallinckrodt Llc Nanoparticle peg modification with h-phosphonates
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
SG11201508469YA (en) 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
US9834529B2 (en) 2014-08-05 2017-12-05 Glaxosmithkline Intellectual Property (No. 2) Limited Synthesis of benzothiazepines
KR101674806B1 (ko) * 2014-10-20 2016-11-10 씨제이헬스케어 주식회사 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
CN109415329B (zh) * 2016-06-27 2023-05-12 葛兰素史克知识产权第二有限公司 合成方法
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
BR112020024479A2 (pt) 2018-06-20 2021-03-02 Albireo Ab hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
HUE060905T2 (hu) 2019-02-06 2023-04-28 Albireo Ab Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
ES2955799T3 (es) 2019-02-06 2023-12-07 Albireo Ab Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares
PL3923943T3 (pl) 2019-02-12 2024-12-09 Mirum Pharmaceuticals, Inc. Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych
CA3158181A1 (en) * 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
ES2973549T3 (es) * 2019-12-04 2024-06-20 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
TWI867107B (zh) * 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
TWI877262B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
CN114786772B (zh) * 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023548788A (ja) 2020-10-20 2023-11-21 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッド 胆汁うっ滞性そう痒症を治療する方法
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用
CN116964041A (zh) * 2020-12-23 2023-10-27 葛兰素史克知识产权第二有限公司 Linerixibat的形式
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
JP2025516153A (ja) 2022-04-22 2025-05-27 アルビレオ・アクチボラグ Asbt阻害剤の皮下投与
KR20250022025A (ko) 2022-06-09 2025-02-14 알비레오 에이비 간염 치료
CN119487013A (zh) 2022-07-05 2025-02-18 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AU2023390975A1 (en) 2022-12-09 2025-06-05 Albireo Ab Asbt inhibitors in the treatment of renal diseases
CN121263187A (zh) 2023-06-06 2026-01-02 葛兰素史密斯克莱知识产权(第2号)有限公司 回肠胆汁酸转运蛋白抑制剂用于治疗瘙痒的新用途
WO2025078973A1 (en) 2023-10-09 2025-04-17 Assia Chemical Industries Ltd. Solid state forms of linerixibat and process for preparation thereof
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2370015A (en) 1933-07-24 1945-02-20 Merck & Co Inc Derivatives of tertiary amino aliphatic acids
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
WO2002053548A1 (fr) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Derives de la benzothiazepine
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
BR0306643A (pt) * 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
JP2006517415A (ja) 2003-01-09 2006-07-27 ジェネンテック・インコーポレーテッド ポリペプチドの精製
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
US7605168B2 (en) 2004-09-03 2009-10-20 Plexxikon, Inc. PDE4B inhibitors
CA2744817C (en) * 2008-11-26 2020-07-07 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes

Similar Documents

Publication Publication Date Title
JP2013525444A5 (https=)
JP2015501783A5 (https=)
JP2013014622A5 (https=)
JP2013509429A5 (https=)
HRP20210343T1 (hr) Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola
JP2012255026A5 (https=)
JP2016518337A5 (https=)
JP2013522326A5 (https=)
JP2012092110A5 (https=)
JP2011105738A5 (https=)
JP2011518833A5 (https=)
JP2013032389A5 (https=)
JP2009545527A5 (https=)
JP2012193216A5 (https=)
JP2013532687A5 (https=)
JP2014515013A5 (https=)
JP2012500090A5 (https=)
JP2012107057A5 (https=)
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
JP2010529118A5 (https=)
JP2015155440A5 (https=)
JP2012502037A5 (https=)
JP2010525055A5 (https=)
JP2014530840A5 (https=)
JP2015516419A5 (https=)